15807 Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28
Thaçi, Diamant, Iversen, Lars, Pau-Charles, Ignasi, López, Andreu Schoenenberger, Blauvelt, Andrew, Puig, LluÃsVolume:
83
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2020.06.730
Date:
December, 2020
File:
PDF, 312 KB
2020